


CLAIMS

CLAIM 1

A compound represented by the formula (I), or a salt, hydrate or solvate thereof:

[Chemical Formula 1]



[wherein

R¹ represents a substituent or a hydrogen atom;

R² represents ~~an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group;~~

(I) a C₁₋₆ alkyl group,

a C₁₋₆ alkyl group having 1 to 3 five- or six-membered monocyclic aromatic heterocyclic groups, or

a C₁₋₆ alkyl group having 1 to 3 five- or six-membered monocyclic aromatic heterocyclic groups, said five- or six-membered monocyclic aromatic heterocyclic groups having 1 to 3 C₁₋₆ alkyl groups that is optionally halogenated, or


(II) a C₇₋₁₆ aralkyl group that is optionally halogenated;

R⁶ and R⁷ each independently represent a hydrogen atom, or a halogen atom ~~or an optionally substituted hydrocarbon group;~~ and

ring A represents a bicyclic aromatic heterocycle selected from the following formulas

(1), (2), (3), (4) and (5):

[Chemical formula 2]



wherein Xs each independently represent N or C(R⁵); and

R³, R⁴ and R⁵ each independently represent a hydrogen atom or a substituent.].


CLAIM 2

The compound or salt, hydrate or solvate thereof according to claim 1, wherein R^2 is

~~(I) a C_{1-6} -alkyl group optionally having 1 to 3 five- or six-membered monocyclic aromatic heterocyclic groups optionally having 1 to 3 optionally halogenated C_{1-6} -alkyl groups;~~
~~or~~
~~(II) an optionally halogenated C_{7-16} -alkyl group~~
a methyl group having one five-membered aromatic heterocyclic group selected from 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-thiadiazolyl and isoxazolyl, said five-membered aromatic heterocyclic group having 1 to 3 substituents selected from methyl, difluoromethyl, difluoroethyl, fluoroisopropyl and fluoroethyl group.

CLAIM 3

The compound or salt, hydrate or solvate thereof according to claim 1, wherein ring A is
a bicyclic aromatic heterocycle represented by the following formula (1)



(1)

CLAIM 4

The compound or salt, hydrate or solvate thereof according to claim 1, wherein R^3 is a hydrogen atom;

R^4 is (a) an amino group optionally monosubstituted or disubstituted with a C_{1-6} alkyl group, or

(b) a C_{1-6} alkoxy group; and

R^5 is (a) a C_{1-6} alkoxy group, or

(b) a C_{1-6} alkyl group optionally having 1 to 3 hydroxy groups.

CLAIM 5

The compound or salt, hydrate or solvate thereof according to claim 1, wherein
R¹ is

(I) a C₁₋₆ alkyl group optionally having 1 to 5 substituents each selected from

(a) a halogen atom,

(b) a hydroxy group,

(c) a cyano group,

(d) a C₁₋₆ alkoxy group optionally having 1 to 3 substituents each selected from

(i) a halogen atom, and

(ii) a hydroxy group, and

(e) a three- to eight-membered nonaromatic heterocyclic group optionally having 1 to 3
halogen atoms;

(II) a three- to eight-membered nonaromatic heterocyclic group optionally having 1 to 5
substituents each selected from

(a) a C₁₋₆ alkoxy group,

(b) a halogen atom, and

(c) a hydroxy group;

(III) a five- to fourteen-membered aromatic heterocyclic group optionally having 1 to 3
optionally halogenated C₁₋₆ alkyl groups;

(IV) a C₁₋₆ alkoxy group optionally having 1 to 5 substituents each selected from

(a) a hydroxy group,

(b) a three- to eight-membered nonaromatic heterocyclic group, and

(c) a five- or six-membered monocyclic aromatic heterocyclic group optionally having 1
to 3 optionally halogenated C₁₋₆ alkyl groups;

(V) an optionally halogenated C₃₋₁₀ cycloalkyl group; or

(VI) an amino group optionally monosubstituted or disubstituted with a C₁₋₆ alkyl group
optionally having 1 to 5 substituents each selected from

(a) (i) a halogen atom,

(ii) a hydroxy group, and

(iii) a C₁₋₆ alkoxy group;

R² is

~~(I) a C₁₋₆ alkyl group optionally having 1 to 3 five- to fourteen-membered aromatic
heterocyclic groups optionally having 1 to 3 substituents each selected from~~

- ~~_____ (a) a halogen atom;~~
- ~~_____ (b) a C₁₋₆ alkyl group optionally having 1 to 7 substituents each selected from~~
- ~~_____ (i) a halogen atom;~~
- ~~_____ (ii) a hydroxy group, and~~
- 5 ~~_____ (iii) a C₁₋₆ alkoxy group;~~
- ~~_____ (e) an optionally halogenated C₃₋₁₀ cycloalkyl group;~~
- ~~_____ (d) a C₁₋₆ alkoxy group;~~
- ~~_____ (e) a C₁₋₆ alkyl group-C₃₋₁₀ cycloalkyl group~~
- ~~_____ (f) a C₁₋₆ alkyl group three to eight membered monocyclic nonaromatic heterocyclic-~~
- 10 ~~group, and~~
- ~~_____ (g) an oxo group; or~~
- ~~_____ (II) a C₇₋₁₆ aralkyl group optionally having 1 to 3 substituents each selected from~~
- ~~_____ (a) a C₁₋₆ alkyl group optionally having 1 to 3 substituents each selected from~~
- ~~_____ (i) a halogen atom, and~~
- 15 ~~_____ (ii) a hydroxy group;~~
- ~~_____ (b) a C₁₋₆ alkoxy-carbonyl group;~~
- ~~_____ (c) a halogen atom;~~
- ~~_____ (d) a C₁₋₆ alkoxy group optionally having 1 to 3 substituents each selected from~~
- ~~_____ (i) a halogen atom, and~~
- 20 ~~_____ (ii) a hydroxy group~~
- ~~_____ (e) a mono- or di-C₁₋₆ alkyl-carbamoyl group;~~
- ~~_____ (f) a cyano group;~~
- ~~_____ (g) an amino group optionally monosubstituted or disubstituted with a substituent~~
- ~~selected from~~
- 25 ~~_____ (i) a C₁₋₆ alkyl group, and~~
- ~~_____ (ii) a C₁₋₆ alkoxy-carbonyl group;~~
- ~~_____ (h) a nitro group, and~~
- ~~_____ (i) a carboxy group;~~

each of R⁶ and R⁷ is a hydrogen atom;

30 ring A is a bicyclic aromatic heterocycle selected from the formulae (1), (2), (3) and (4);

Xs each independently represent C(R⁵) or N;

R³ is a hydrogen atom;

R⁴ is

(I) a hydrogen atom,

- (II) a halogen atom,
(III) an optionally halogenated C₁₋₆ alkoxy group, or
(IV) an amino group optionally monosubstituted or disubstituted with a C₁₋₆ alkyl group; and

5 R⁵ is

- (I) a hydrogen atom,
(II) a halogen atom,
(III) a cyano group,
(IV) a C₁₋₆ alkyl group optionally having 1 to 5 substituents each selected from

- 10 (a) a halogen atom,
(b) a C₁₋₆ alkoxy group,
(c) a C₁₋₆ alkoxy-C₁₋₆ alkoxy group,
(d) a hydroxy group, and

- (e) a C₁₋₆ alkyl-carbonyloxy group,
15 (V) a C₁₋₆ alkoxy group,
(VI) a C₂₋₆ alkenyl group optionally having 1 to 3 C₁₋₆ alkoxy groups,
(VII) a C₂₋₆ alkynyl group,
(VIII) a cyano-C₆₋₁₄ aryl group,
(IX) a five- to fourteen-membered aromatic heterocyclic group optionally

20 having 1 or 2 C₁₋₆ alkyl groups optionally having 1 to 3 substituents each selected from

- (a) a halogen atom,
(b) a five- or six-membered monocyclic aromatic heterocyclic group,

and

- (c) a three- to eight-membered monocyclic nonaromatic heterocyclic

25 group,

- (X) a C₁₋₆ alkyl-carbonyl group,
(XI) a hydroxy group,
(XII) a C₁₋₆ alkyl-five- to fourteen-membered aromatic heterocyclic oxy group,
(XIII) a three- to eight-membered monocyclic nonaromatic heterocyclic group

30 optionally having 1 to 3 substituents each selected from

- (a) a halogen atom,
(b) a C₁₋₆ alkoxy group, and
(c) an oxo group, or

- (XIV) an amino group optionally monosubstituted or disubstituted with an

optionally halogenated C₁₋₆ alkyl.

CLAIM 6

5 A medicament comprising the compound or salt, hydrate or solvate thereof according to claim 1.

CLAIM 7

10 The medicament according to claim 6, which is a CLK inhibitor.

CLAIM 8

15 The medicament according to claim 6, which is suitable for use as a prophylactic or therapeutic agent for cancer.

CLAIM 9

20 The compound or salt, hydrate or solvate thereof according to claim 1, suitable for use in inhibiting CLK in a mammal, wherein an effective amount of the compound or a salt thereof is to be administered to the mammal.

CLAIM 10

25 The compound or salt, hydrate or solvate thereof according to claim 1 for use in the prevention or treatment of cancer.

CLAIM 11

 Use of the compound or salt, hydrate or solvate thereof according to claim 1 in the manufacture of a medicament for the prophylactic or therapeutic treatment of cancer.

30 CLAIM 12

 The compound or salt, hydrate or solvate thereof according to claim 1 for use in medicine.